Adjuvant Treatment of GIST: Patient Selection and Treatment Strategies

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2012 Apr 25

PMID 22525709

Citations 34

Authors

Heikki Joensuu

Affiliations

Soon will be listed here.

Abstract

Tyrosine kinase inhibitors that target the key molecular drivers of gastrointestinal stromal tumour (GIST) are effective treatments of advanced-stage GIST. Yet, most of these patients succumb to the disease. Approximately 60% of patients with GIST are cured by surgery, and these individuals can be identified by risk stratification schemes based on tumour size, mitosis count and site, and assessment of rupture. Two large randomized trials have evaluated imatinib as adjuvant treatment for operable, KIT-positive GIST; adjuvant imatinib substantially improved time to recurrence. One of these trials reported that 3 years of adjuvant imatinib improves overall survival of patients who have a high estimated risk for recurrence of GIST compared with 1 year of imatinib. The optimal adjuvant strategy remains unknown and some patients might benefit from longer than 3 years of imatinib treatment. However, a strategy that involves GIST risk assessment following surgery using a validated scheme, administration of adjuvant imatinib for 3 years, patient monitoring during and after completion of imatinib to detect recurrence early, and reinstitution of imatinib if GIST recurs is a reasonable choice for care of patients with high-risk GIST.

Citing Articles

Nomogram for predicting cardiovascular mortality in patients with gastrointestinal stromal tumor: A population-based study.

Wang H, Zheng K, Tai C, Sun Y, Feng S, Zhang Y Medicine (Baltimore). 2024; 103(39):e39835.

PMID: 39331912 PMC: 11441931. DOI: 10.1097/MD.0000000000039835.

Managing locally advanced GIST complicated by perforation: A case report and comprehensive review.

Grabill N, Louis M, Cawthon M, Conway J, Chambers J Radiol Case Rep. 2024; 19(11):4824-4831.

PMID: 39228941 PMC: 11367461. DOI: 10.1016/j.radcr.2024.07.105.

Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies.

Yu Y, Yu M, Luo L, Zhang Z, Zeng H, Chen Y Front Oncol. 2024; 14:1405727.

PMID: 39070147 PMC: 11272528. DOI: 10.3389/fonc.2024.1405727.

USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition.

Sun H, Cui Z, Li C, Gao Z, Xu J, Bian Y Adv Sci (Weinh). 2024; 11(34):e2401171.

PMID: 38973363 PMC: 11425886. DOI: 10.1002/advs.202401171.

The development of a prediction model based on deep learning for prognosis prediction of gastrointestinal stromal tumor: a SEER-based study.

Zeng J, Li K, Cao F, Zheng Y Sci Rep. 2024; 14(1):6609.

PMID: 38504089 PMC: 10951333. DOI: 10.1038/s41598-024-56701-2.

References

Heinrich M, Corless C, Duensing A, McGreevey L, Chen C, Joseph N . PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299(5607):708-10. DOI: 10.1126/science.1079666. View

DeMatteo R, Ballman K, Antonescu C, Maki R, Pisters P, Demetri G . Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373(9669):1097-104. PMC: 2915459. DOI: 10.1016/S0140-6736(09)60500-6. View

Bardsley M, Horvath V, Asuzu D, Lorincz A, Redelman D, Hayashi Y . Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology. 2010; 139(3):942-52. PMC: 2933938. DOI: 10.1053/j.gastro.2010.05.083. View

Davies H, Wathen C, Gleeson F . The risks of radiation exposure related to diagnostic imaging and how to minimise them. BMJ. 2011; 342:d947. DOI: 10.1136/bmj.d947. View

Crosby J, Catton C, Davis A, Couture J, OSullivan B, Kandel R . Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001; 8(1):50-9. DOI: 10.1007/s10434-001-0050-4. View

Verweij J, Casali P, Zalcberg J, Lecesne A, Reichardt P, Blay J . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364(9440):1127-34. DOI: 10.1016/S0140-6736(04)17098-0. View

Eisenberg B, Trent J . Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer. 2011; 129(11):2533-42. PMC: 7596877. DOI: 10.1002/ijc.26234. View

Rutkowski P, Bylina E, Wozniak A, Nowecki Z, Osuch C, Matlok M . Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol. 2011; 37(10):890-6. DOI: 10.1016/j.ejso.2011.06.005. View

Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E . Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer. 2003; 106(6):887-95. DOI: 10.1002/ijc.11323. View

10.

Emile J, Brahimi S, Coindre J, Bringuier P, Monges G, Samb P . Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol. 2011; 29(3):1765-72. DOI: 10.1007/s12032-011-0074-y. View

11.

Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L . DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010; 57(2):259-70. DOI: 10.1111/j.1365-2559.2010.03624.x. View

12.

Park S, Ryu M, Ryoo B, Im S, Kwon H, Lee S . Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs. 2012; 30(6):2377-83. DOI: 10.1007/s10637-012-9795-9. View

13.

Joensuu H, de Braud F, Grignagni G, De Pas T, Spitalieri G, Coco P . Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer. 2011; 104(11):1686-90. PMC: 3111164. DOI: 10.1038/bjc.2011.151. View

14.

DeMatteo R, Gold J, Saran L, Gonen M, Liau K, Maki R . Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2007; 112(3):608-15. DOI: 10.1002/cncr.23199. View

15.

Agaram N, Wong G, Guo T, Maki R, Singer S, DeMatteo R . Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008; 47(10):853-9. PMC: 2902874. DOI: 10.1002/gcc.20589. View

16.

Mazzola P, Spitale A, Banfi S, Mazzucchelli L, Frattini M, Bordoni A . Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): a population-based study in the South of Switzerland, 1999-2005. Histol Histopathol. 2008; 23(11):1379-86. DOI: 10.14670/HH-23.1379. View

17.

Debiec-Rychter M, Sciot R, Cesne A, Schlemmer M, Hohenberger P, van Oosterom A . KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006; 42(8):1093-103. DOI: 10.1016/j.ejca.2006.01.030. View

18.

Reichardt P, Blay J, Gelderblom H, Schlemmer M, Demetri G, Bui-Nguyen B . Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol. 2012; 23(7):1680-7. DOI: 10.1093/annonc/mdr598. View

19.

Joensuu H, Eriksson M, Hall K, Hartmann J, Pink D, Schutte J . One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012; 307(12):1265-72. DOI: 10.1001/jama.2012.347. View

20.

Heinrich M, Corless C, Demetri G, Blanke C, von Mehren M, Joensuu H . Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23):4342-9. DOI: 10.1200/JCO.2003.04.190. View